ETHACRYNATE SODIUM DIN 02462362
Status: Marketed
Holder: STERIMAX INC
Molecule: ETHACRYNIC ACID (ETHACRYNATE SODIUM)
Available to quote
Health Canada record
| Active ingredient(s) | ETHACRYNIC ACID (ETHACRYNATE SODIUM) 50 MG |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | C03CC01 ETACRYNIC ACID |
| Original market date | 22-May-2018 |
| Current status date | 29-Feb-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Sterimax Inc — licence 100925, currently licensed, last inspection rating C (2024-05-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ETHACRYNIC ACID (ETHACRYNATE SODIUM)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02479591 | ETHACRYNATE SODIUM FOR INJECTION | ENDO PAR INNOVATION COMPANY, LLC | Powder For Solution | ETHACRYNIC ACID (ETHACRYNATE SODIUM) 50 MG | Cancelled Pre Market |
| 02469456 | ETHACRYNATE SODIUM FOR INJECTION USP | STERIMAX INC | Powder For Solution | ETHACRYNIC ACID (ETHACRYNATE SODIUM) 50 MG | Dormant |
| 00268313 | SODIUM EDECRIN | BAUSCH HEALTH, CANADA INC. | Powder For Solution | ETHACRYNIC ACID (ETHACRYNATE SODIUM) 50 MG | Dormant |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 32792 | 2024-02-29 | Abbreviated New Drug Submission (ANDS) | Administrative: Change in Product Ownership |
| 19058 | 2017-03-10 | Abbreviated New Drug Submission (ANDS) |